Suggested remit - To appraise the clinical and cost effectiveness of durvalumab with tremelimumab within its marketing authorisation for untreated metastatic urothelial cancer
Status In progress
Process STA 2018
ID number 1335

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
19 October 2018 - 16 November 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
24 April 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance